end of treatment (ie, 2.5 years after randomisation). 222 deaths occurred in the exemestane group compared with 261 deaths in the tamoxifen groupOur results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen...